TTrialPathMatch Me to Trials
← Back to trials
RecruitingAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Eligible age

18+ yrs

Accepts

All genders

Locations

36 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.

Sponsor: National Cancer Institute (NCI)

You may qualify if…

  • ✓ STEP 0: Patient must be ≥ 18 years of age
  • ✓ STEP 0: Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 28 days prior to Step 0 pre-registration
  • ✓ STEP 0: Patient must be a postmenopausal woman or a man
  • ✓ NOTE: Menopause can be determined by any of the following:
  • ✓ Prior bilateral oophorectomy
  • ✓ Age ≥ 60 years
  • ✓ Age \< 60 years with amenorrhea for ≥ 12 months and estradiol and follicle stimulating hormone (FSH) levels in the postmenopausal range
  • ✓ NOTE: FSH and estradiol levels should be repeated as clinically indicated to ensure menopausal status in patients with breast cancer with chemotherapy-induced amenorrhea

Where it's recruiting

Arkansas

Jonesboro

California

Auburn · Berkeley · Beverly Hills · Fremont …

Colorado

Westminster

Connecticut

Stamford

Delaware

Millville · Newark · Rehoboth Beach

Florida

Lakeland

Idaho

Coeur d'Alene · Post Falls · Sandpoint

Illinois

Bloomington · Canton · Carterville · Carthage …

Indiana

Avon · Carmel · Indianapolis

Iowa

Ames · Ankeny · Carroll · Cedar Rapids …

Kansas

Hays · Kansas City · Olathe · Overland Park …

Louisiana

New Orleans

Source: ClinicalTrials.gov · NCT07391774 · last updated 2026-11-20